Sarepta Therapeutics, Inc. (SRPT)

NASDAQ: SRPT · USD

$19.3

+0.41 (+2.2%)· Recorded snapshot

Market cap	2B
Revenue (ttm)	2B
Net income (ttm)	-136.7M
EPS (ttm)	-$1.32
Shares out	105.6M
P/E (forward)	84.9x
Volume	1,054,258
Beta	0.38

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2B
Net income (ttm): -136.7M
EPS (ttm): -$1.32
P/E (forward): 84.9x
Market cap: 2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E84.9

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-9.5

P25 n/aP50 n/aP75 n/a

ROIC-3.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All SRPT indicators

Market & fundamental data

Available fields

230

Groups with data

Currency

USD

Showing 230 of 230 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000873303
Company name	Sarepta Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	803607100
Earnings date	2026-11-05
Earnings time	amc
Employees	835
Employees change	-537
Employees growth	-39.14%
Enterprise value	$2.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1980
In index	RUSSELL2000
Industry	Biotechnology
IPO date	1997-06-03
Is primary listing	Yes
Is SPAC	No
ISIN number	US8036071004
Last 10-K release date	2026-03-02
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split date	2012-07-12
Last stock split type	Reverse
Market cap	$2B
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$19.30
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	SRPT
U.S. state	Massachusetts
Website	https://www.sarepta.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	214.44x
Earnings yield	-6.82%
EV/FCF	27.87x
EV/Sales	1.16x
FCF / EV yield	3.59%
FCF yield	4.08%
Forward EV/Sales	1.63x
Forward P/E	84.94x
Forward P/S	1.43x
P/(OCF - SBC) ratio	164.63x
P/B ratio	1.31x
P/FCF ratio	24.53x
P/OCF ratio	18.08x
P/S ratio	1.02x
Price / tangible book value	1.34x
Sector forward P/E	23.53x
Sector P/E	51.01x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-3.15%
EBITDA margin	-0.89%
FCF margin	4.15%
Gross margin	19.11%
Operating margin	-3.15%
Pretax margin	-6.63%
Profit margin	-6.93%
Profit per employee	$-163,743
Revenue per employee	$2.4M
ROA	-1.13%
ROA (5Y)	-6.49%
ROCE	-2.32%
ROE	-9.48%
ROE (5Y)	-55.33%
ROIC	-3.36%
SBC / revenue	5%
Tax / revenue	0.29%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
FCF growth (Q)	-14.39%
Gross profit growth	-33.24%
Gross profit growth (Q)	-36.8%
Net income growth years	0
OCF growth (Q)	-24.59%
Operating income growth (Q)	-54.76%
Revenue growth	-20.44%
Revenue growth (Q)	-34.34%
Revenue growth (QoQ)	-45.09%
Revenue growth 10Y	108.81%
Revenue growth 3Y	25.31%
Revenue growth 5Y	26.89%
Revenue growth years	10

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-29.2M
Depreciation and amortization	$44.7M
EBIT	$-62.2M
EBITDA	$-17.5M
EPS	$-1.32
FCF per share	$0.77
Financing cash flow	$-156.8M
Free cash flow	$81.8M
Free cash flow minus SBC	$-17M
Gross profit	$377.3M
Income taxes	$5.8M
Investing cash flow	$100.8M
Net borrowing	$-159.1M
Net cash flow	$55.1M
Net income	$-136.7M
Operating cash flow minus SBC	$12.2M
Operating income	$-62.2M
Revenue	$2B
Stock-based compensation	$98.8M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.07
Book value per share	$14.46
Debt / EBITDA	7.07
Debt / equity	0.7
Debt / FCF	12.98
Interest coverage	-0.87
Long-term assets	$964.7M
Long-term liabilities	$1.2B
Net cash (debt)	$-273.9M
Net cash / market cap	-13.65%
Net debt / equity	0.18
Net debt / FCF	3.35
Piotroski F-Score	4
Property, plant and equipment	$446.8M
Shareholders' equity	$1.5B
Tangible book value	$1.5B
Tangible book value per share	$14.17
Total assets	$3.2B
Total cash	$788.5M
Total debt	$1.1B
Total liabilities	$1.7B
WACC	5.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.57
Current assets	$2.2B
Current liabilities	$502.9M
Current ratio	4.42
Inventory turnover	1.68
Net working capital	$949M
Quick ratio	2.44
Working capital	$1.7B
Working capital turnover	1.14

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-7.36%
Dividend yield	0%
Shareholder yield	-7.36%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-53.57%
10Y return CAGR	-7.39%
10Y total return	-53.57%
150-day SMA	$18.74
15Y price change	206.63%
15Y return CAGR	7.76%
15Y total return	206.63%
1D price change	2.17%
1M price change	1.5%
1M total return	1.5%
1W price change	-1.15%
1W total return	-1.15%
1Y price change	-19.36%
1Y return CAGR	-19.37%
1Y total return	-19.36%
20-day SMA	$17.82
200-day SMA	$18.75
20Y price change	-23.71%
20Y return CAGR	-1.34%
20Y total return	-23.71%
3M price change	19.26%
3M total return	19.26%
3Y price change	-82.26%
3Y return CAGR	-43.81%
3Y total return	-82.26%
50-day SMA	$19.26
50-day SMA vs 200-day SMA	50over200
52-week high	$24.68
52-week high date	2026-01-26
52-week low	$14.68
52-week low date	2026-06-11
5Y price change	-75.48%
5Y return CAGR	-24.51%
5Y total return	-75.48%
6M price change	-9.68%
6M total return	-9.68%
All-time high	$181.83
All-time high date	2020-12-22
All-time low	$2.60
All-time low date	2012-05-18
Average true range (ATR)	$0.97
Average volume	2.9M
Beta (1Y)	2.27
Beta (2Y)	1.39
Beta (5Y)	0.38
Change from 52-week high	-21.8%
Change from 52-week low	31.47%
Change from all-time high	-89.58%
Change from all-time low	628.85%
Change from open	3.49%
Day's gap	-1.27%
Dollar volume	$20.3M
High price	$19.31
Low price	$18.65
Monthly RSI	33.48
Open price	$18.65
Position in 52-week range	98.48%
Premarket change	-1.85%
Premarket close	$18.89
Premarket price	$18.54
Premarket volume	37.3K
Previous close	$18.89
Price vs 150-day SMA	1.15%
Price vs 20-day SMA	6.37%
Price vs 200-day SMA	1.05%
Price vs 50-day SMA	-1.59%
Relative volume	0.36
RSI	54.21
Sharpe ratio	0.08
Sharpe ratio (3Y)	-0.33
Sharpe ratio (5Y)	-0.09
Sortino ratio	0.19
Sortino ratio (3Y)	-0.37
Sortino ratio (5Y)	-0.05
Volume	1.1M
Weekly RSI	50.23
YTD price change	-11.94%
YTD total return	-11.94%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	100.5M
Float percentage	95.19%
Shares change (QoQ)	-13.52%
Shares change (YoY)	7.36%
Shares held by insiders	4.78%
Shares held by institutions	102.45%
Shares outstanding	105.6M
Short % of float	22.66%
Short % of shares	21.57%
Short ratio	7.8 days

Deeper analysis on SRPT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this SRPT report

Is a complete SRPT research report available?

No complete published report is available for Sarepta Therapeutics, Inc. (SRPT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Sarepta Therapeutics, Inc. (SRPT)

Price

Financial snapshot

Fair-value bridge

Latest news · SRPT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SRPT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on SRPT

Frequently asked questions